These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 14764946

  • 1. Discovery and immunologic validation of new antigens for therapeutic cancer vaccines.
    Radvanyi L.
    Int Arch Allergy Immunol; 2004 Feb; 133(2):179-97. PubMed ID: 14764946
    [Abstract] [Full Text] [Related]

  • 2. Prospects and limitations of recombinant poxviruses for prostate cancer immunotherapy.
    Hwang C, Sanda MG.
    Curr Opin Mol Ther; 1999 Aug; 1(4):471-9. PubMed ID: 11713762
    [Abstract] [Full Text] [Related]

  • 3. From genomics to cancer vaccines: patient-tailored or universal vaccines?
    Nadler LM, Schultze JL.
    Curr Opin Mol Ther; 2002 Dec; 4(6):572-6. PubMed ID: 12596359
    [Abstract] [Full Text] [Related]

  • 4. Proteomics approaches towards antigen discovery and vaccine development.
    Klade CS.
    Curr Opin Mol Ther; 2002 Jun; 4(3):216-23. PubMed ID: 12139306
    [Abstract] [Full Text] [Related]

  • 5. DNA vaccines: successes and limitations in cancer and infectious disease.
    Lowe DB, Shearer MH, Kennedy RC.
    J Cell Biochem; 2006 May 15; 98(2):235-42. PubMed ID: 16440328
    [Abstract] [Full Text] [Related]

  • 6. Cancer vaccines: an update with special focus on ganglioside antigens.
    Bitton RJ, Guthmann MD, Gabri MR, Carnero AJ, Alonso DF, Fainboim L, Gomez DE.
    Oncol Rep; 2002 May 15; 9(2):267-76. PubMed ID: 11836591
    [Abstract] [Full Text] [Related]

  • 7. Therapeutic cancer vaccines.
    Acres B, Paul S, Haegel-Kronenberger H, Calmels B, Squiban P.
    Curr Opin Mol Ther; 2004 Feb 15; 6(1):40-7. PubMed ID: 15011780
    [Abstract] [Full Text] [Related]

  • 8. A paradigm shift in therapeutic vaccination of cancer patients: the need to apply therapeutic vaccination strategies in the preventive setting.
    Gray A, Raff AB, Chiriva-Internati M, Chen SY, Kast WM.
    Immunol Rev; 2008 Apr 15; 222():316-27. PubMed ID: 18364011
    [Abstract] [Full Text] [Related]

  • 9. Cancer vaccines.
    Pardoll DM.
    Immunol Today; 1993 Jun 15; 14(6):310-6. PubMed ID: 8397772
    [Abstract] [Full Text] [Related]

  • 10. Tumor antigens as surrogate markers and targets for therapy and vaccines.
    Dalgleish A, Pandha H.
    Adv Cancer Res; 2007 Jun 15; 96():175-90. PubMed ID: 17161680
    [Abstract] [Full Text] [Related]

  • 11. Tumor escape from the immune response: a major hurdle for successful immunotherapy of cancer?
    Chouaib S.
    Tunis Med; 2005 Dec 15; 83 Suppl 12():7-10. PubMed ID: 16430055
    [No Abstract] [Full Text] [Related]

  • 12. Cancer vaccines. Any future?
    Myc LA, Gamian A, Myc A.
    Arch Immunol Ther Exp (Warsz); 2011 Aug 15; 59(4):249-59. PubMed ID: 21644030
    [Abstract] [Full Text] [Related]

  • 13. Vaccine therapy for cancer: fact or fiction?
    Odunsi K, Lele S, Savalgi R.
    Surg Technol Int; 2004 Aug 15; 13():39-47. PubMed ID: 15744673
    [Abstract] [Full Text] [Related]

  • 14. Cancer vaccines: preclinical studies and novel strategies.
    Palena C, Abrams SI, Schlom J, Hodge JW.
    Adv Cancer Res; 2006 Aug 15; 95():115-45. PubMed ID: 16860657
    [Abstract] [Full Text] [Related]

  • 15. Immune responses to human tumors: development of tumor vaccines.
    Platsoucas CD, Fincke JE, Pappas J, Jung WJ, Heckel M, Schwarting R, Magira E, Monos D, Freedman RS.
    Anticancer Res; 2003 Aug 15; 23(3A):1969-96. PubMed ID: 12894571
    [Abstract] [Full Text] [Related]

  • 16. Cancer vaccines inducing antibody production: more pros than cons.
    Jensen-Jarolim E, Singer J.
    Expert Rev Vaccines; 2011 Sep 15; 10(9):1281-9. PubMed ID: 21919618
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Vaccines for immunotherapy of breast cancer and prostate cancer: new developments and comparative aspects.
    Minev BR, Guo F, Gueorguieva I, Kaiser HE.
    In Vivo; 2002 Sep 15; 16(6):405-15. PubMed ID: 12494883
    [Abstract] [Full Text] [Related]

  • 19. Optimization of antitumor immunotherapy mediated by type III secretion system-based live attenuated bacterial vectors.
    Wang Y, Gouëllec AL, Chaker H, Asrih H, Polack B, Toussaint B.
    J Immunother; 2012 Apr 15; 35(3):223-34. PubMed ID: 22421940
    [Abstract] [Full Text] [Related]

  • 20. Current developments with peptide-based human tumor vaccines.
    Khazaie K, Bonertz A, Beckhove P.
    Curr Opin Oncol; 2009 Nov 15; 21(6):524-30. PubMed ID: 19770763
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.